Gene Hung

Gene Hung, M.D., co-founded XinThera in 2021 and serves as its Senior Vice President of Research. He is a seasoned veteran in the field of drug discovery. Previously Gene co-founded small molecule inflammation biotech FronThera in 2015 and served as its Senior Vice President of Biology and Drug Discovery through its successful acquisition in February 2021. He was an executive director at Ionis Pharmaceuticals for over a decade, where he led the drug discovery programs contributing to creating Spinraza, the first drug approved for spinal muscular atrophy (2016), and HTTRx, which advanced to Phase 3 for Huntington's disease. Gene also served as Director at Arena Pharmaceuticals. His prior tenure at House Ear Institute/USC as an assistant professor in gene therapy exemplifies his true passion in patient outcome care. Gene obtained his M.D. from Tianjing Medical College, achieved his residency in Tong Ren Hospital, and acquired his Post-Doc at USC. He is a co-inventor on eight patents and a co-author of fifty publications.